Literature DB >> 14967729

Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy.

Su Min Chang1, Nasser M Lakkis, Jennifer Franklin, William H Spencer, Sherif F Nagueh.   

Abstract

BACKGROUND: Alcohol septal ablation (ASA) therapy results in clinical and hemodynamic improvement in patients with hypertrophic obstructive cardiomyopathy. However, a subset remains symptomatic afterward, requiring additional procedures. We sought to examine the determinants of an unsatisfactory outcome, defined as unchanged symptoms with <50% reduction of baseline left ventricular outflow tract (LVOT) gradient. METHODS AND
RESULTS: Of 173 consecutive hypertrophic obstructive cardiomyopathy patients who underwent ASA, 39 had an unsatisfactory outcome after the first procedure. Patients with an unsatisfactory outcome had a higher baseline LVOT gradient, fewer septal arteries injected with ethanol, lower peak creatine kinase (CK), smaller septal area opacified by contrast echocardiography, and higher residual gradient in the catheterization laboratory after ASA (all P<0.05). Symptoms, septal thickness, mitral regurgitation severity, and ventricular function were not determinants of outcome. On multiple logistic regression, LVOT gradient reduction after ASA in the catheterization laboratory to > or =25 mm Hg (OR, 5.5; P=0.01) and peak CK <1300 U/L (OR, 2.5; P=0.04) were the independent predictors of an unsatisfactory outcome.
CONCLUSIONS: The residual LVOT gradient in the catheterization laboratory and peak CK leak after ASA are the independent predictors of ASA outcome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14967729     DOI: 10.1161/01.CIR.0000117089.99918.5A

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  13 in total

Review 1.  Alcohol septal ablation for obstructive hypertrophic cardiomyopathy.

Authors:  Charles J Knight
Journal:  Heart       Date:  2006-09       Impact factor: 5.994

2.  Increasing evidence for the safety and efficacy of alcohol septal ablation during medium- and long-term follow-up.

Authors:  M Pauschinger; A Keren
Journal:  Clin Res Cardiol       Date:  2007-11-05       Impact factor: 5.460

3.  One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response.

Authors:  L Faber; D Welge; D Fassbender; H K Schmidt; D Horstkotte; H Seggewiss
Journal:  Clin Res Cardiol       Date:  2007-09-25       Impact factor: 5.460

4.  Basal infarct location but not larger infarct size is associated with a successful outcome after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: a cardiovascular magnetic resonance imaging study.

Authors:  Robbert C Steggerda; Christiane A Geluk; Wessel Brouwer; Albert C van Rossum; Jurriën M Ten Berg; Maarten P van den Berg
Journal:  Int J Cardiovasc Imaging       Date:  2015-02-01       Impact factor: 2.357

5.  Pathological effects of alcohol septal ablation for hypertrophic obstructive cardiomyopathy.

Authors:  A L Baggish; R N Smith; I Palacios; G J Vlahakes; D M Yoerger; M H Picard; P A Lowry; I-K Jang; M A Fifer
Journal:  Heart       Date:  2006-06-28       Impact factor: 5.994

6.  Catheter-based septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: follow-up results of the TASH-registry of the German Cardiac Society.

Authors:  L Faber; H Seggewiss; F H Gietzen; H Kuhn; P Boekstegers; L Neuhaus; L Seipel; D Horstkotte
Journal:  Z Kardiol       Date:  2005-08

7.  Hypertrophic obstructive cardiomyopathy: the Mayo Clinic experience.

Authors:  Kunal D Kotkar; Sameh M Said; Joseph A Dearani; Hartzell V Schaff
Journal:  Ann Cardiothorac Surg       Date:  2017-07

Review 8.  [Cardiomyopathies II. Hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy].

Authors:  H-P Schultheiss; M Noutsias; U Kühl; U Gross; D Lassner; W Poller; M Pauschinger
Journal:  Internist (Berl)       Date:  2005-12       Impact factor: 0.743

Review 9.  The "1st septal unit" in hypertrophic obstructive cardiomyopathy: a newly recognized anatomo-functional entity, identified during recent alcohol septal ablation experience.

Authors:  Paolo Angelini
Journal:  Tex Heart Inst J       Date:  2007

Review 10.  Percutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: From Experiment to Standard of Care.

Authors:  Lothar Faber
Journal:  Adv Med       Date:  2014-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.